Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers

Xenobiotica

Volumn 42, Issue 11, 2012, Pages 1128-1137

  Samuelsson, Kristin ^a   Pickup, Kathryn ^a   Sarda, Sunil ^a   Swales, John G ^a   Morikawa, Yoshio ^b   Schulz Utermoehl, Timothy ^a,c   Hutchison, Michael ^a   Wilson, Ian D ^a  

^a ASTRAZENECA   (United Kingdom)

^b PhoenixBio USA Corporation   (Japan)

^c Shire Pharmaceuticals   (United Kingdom)

Author keywords

Microsampling; Midazolam; PXB chimeric mouse model

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; DRUG METABOLITE; MIDAZOLAM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; QUANTITATIVE ANALYSIS;

ANIMALS; BIOTRANSFORMATION; CHILD, PRESCHOOL; CHIMERA; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MICE; MICE, SCID; MIDAZOLAM;

ANIMALIA; MUS;

EID: 84867157232     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.689888     Document Type: Article

References (33)

1. Anderson S, Luffer-Atlas D, Knadler MP. (2009). Predicting circulating human metabolites: how good are we? Chem Res Toxicol 22:243-256.
2. Aoki K, Kashiwagura Y, Horie T, Sato H, Tateno C, Ozawa N, Yoshizato K. (2006). Characterization of humanized liver from chimeric mice using coumarin as a human CYP2A6 and mouse CYP2A5 probe. Drug Metab Pharmacokinet 21:277-285.
3. Bauer TM, Ritz R, Haberthür C, Ha HR, Hunkeler W, Sleight AJ, Scollo- Lavizzari G, Haefeli WE. (1995). Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 346:145-147.
4. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, Smith DA. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357-368.
5. Dresser GK, Spence JD, Bailey DG. (2000). Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57. (Pubitemid 30055093)
6. Guengerich FP. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17. (Pubitemid 29222549)
7. Guengerich FP. (2003). Cytochromes P450, drugs, and diseases. Mol Interv 3:194-204.
8. Guo T, Mao GF, Xia DY, Su XY, Zhao LS. (2011). Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. J Clin Pharm Ther 36:406-411.
9. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. (2004). In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 76:428-440. (Pubitemid 39469867)
10. Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413. (Pubitemid 11134120)
11. Heizmann P, Eckert M, Ziegler WH. (1983). Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 16 Suppl 1:43S-49S. (Pubitemid 13006585)
12. Heizmann P, Ziegler WH. (1981). Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung 31:2220-2223. (Pubitemid 12222301)
13. Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, Jones B. (2009). In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 67:445-454.
14. Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S. (2008). CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:2429-2433.
15. Inoue T, Sugihara K, Ohshita H, Horie T, Kitamura S, Ohta S. (2009). Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 24:153-160.
16. Kamimura H, Nakada N, Suzuki K, Mera A, Souda K, Murakami Y, Tanaka K, Iwatsubo T, Kawamura A, Usui T. (2010). Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 25:223-235.
17. Katoh M, Yokoi T. (2007). Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev 39:145-157.
18. Kitamura S, Nitta K, Tayama Y, Tanoue C, Sugihara K, Inoue T, Horie T, Ohta S. (2008). Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:1202-1205. (Pubitemid 351929332)
19. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. (1989). Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96. (Pubitemid 19191264)
20. Lamba JK, Lin YS, Schuetz EG, Thummel KE. (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294. (Pubitemid 35284253)
21. Lootens L, Meuleman P, Leroux-Roels G, Van Eenoo P. (2011). Metabolic studies with promagnon, methylclostebol and methasterone in the uPA+/+-SCID chimeric mice. J Steroid Biochem Mol Biol 127:374-381.
22. Martens-Lobenhoffer J, Eisenhardt S, Tröger U, Röse W, Meyer FP. (2001). The effect of anxiety and personality on the pharmacokinetics of oral midazolam. Anesth Analg 92:621-624. (Pubitemid 32185100)
23. Okumura H, Katoh M, Sawada T, Nakajima M, Soeno Y, Yabuuchi H, Ikeda T, Tateno C, Yoshizato K, Yokoi T. (2007). Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 97:533-538. (Pubitemid 47073867)
24. Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr. (2003). An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 73:153-158. (Pubitemid 36269666)
25. Schulz-Utermoehl T, Sarda S, Foster JR, Jacobsen M, Kenna JG, Morikawa Y, Salmu J, Gross G, Wilson ID. (2012). Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers. Xenobiotica 42:503-517.
26. Seo KA, Bae SK, Choi YK, Choi CS, Liu KH, Shin JG. (2010). Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos 38:2007-2013.
27. De Serres M, Bowers G, Boyle G, Beaumont C, Castellino S, Sigafoos J, Dave M, Roberts A, Shah V, Olson K, Patel D, Wagner D, Yeager R, Serabjit-Singh C. (2011). Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 41:464-475.
28. Streetman DS, Bertino JS Jr, Nafziger AN. (2000). Phenotyping of drugmetabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216. (Pubitemid 30242736)
29. Strom SC, Davila J, Grompe M. (2010). Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 640:491-509.
30. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa T, Yoshizato K. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901-912. (Pubitemid 39129297)
31. Yamazaki H, Kuribayashi S, Inoue T, Tateno C, Nishikura Y, Oofusa K, Harada D, Naito S, Horie T, Ohta S. (2010). Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by twodimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol 23:152-158.
32. Yoshizato K, Tateno C. (2009). In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 5:1435-1446.
33. Zhu B, Bush D, Doss GA, Vincent S, Franklin RB, Xu S. (2008). Characterization of 1'-hydroxymidazolam glucuronidation in human liver microsomes. Drug Metab Dispos 36: 331-338. (Pubitemid 351185745)